Potassium channel, inwardly rectifying subfamily J member 11 (KCNJ11)

Potassium channel, inwardly rectifying subfamily J member 11 (KCNJ11), also known as Kir6.2, is a critical protein that forms the pore-conducting subunit of the ATP-sensitive potassium (K-ATP) channel (UniProt: Q14654). Primarily expressed in pancreatic beta cells, cardiomyocytes, and skeletal muscle, it works in conjunction with the regulatory sulfonylurea receptor 1 (SUR1) to couple the metabolic state of the cell to its membrane potential (NCBI Gene: 3767). In pancreatic beta cells, an increase in the ATP/ADP ratio leads to the closure of KCNJ11 channels, triggering membrane depolarization, calcium influx, and the subsequent release of insulin (StatPearls: Insulin Secretion). Mutations in the KCNJ11 gene are major drivers of glucose metabolism disorders, including permanent neonatal diabetes and congenital hyperinsulinism (PubMed: 15319439). Therapeutically, KCNJ11 is the primary target for sulfonylureas and meglitinides, which are used to manage type 2 diabetes by promoting insulin secretion. Understanding the structure and function of KCNJ11 is essential for developing precision medicine approaches for patients with specific genetic forms of diabetes.

Other names

Kir6.2Inward rectifier K+ channel Kir6.2ATP-sensitive inward rectifier potassium channel 11BIRHHF2TNDM3PHHIMODY13

Drugs like sulfonylureas and meglitinides act as inhibitors that bind to the associated SUR1 subunit, causing the KCNJ11 channel to close, which leads to cell depolarization and subsequent insulin release (PubMed: 15319439). Conversely, potassium channel openers like diazoxide stabilize the open state of the channel to inhibit insulin secretion (StatPearls: Insulin Secretion).